Literature DB >> 8517426

Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group.

J M Neutel1, D H Smith, C V Ram, M P Lefkowitz, M K Kazempour, M A Weber.   

Abstract

The antihypertensive effects of drugs are partly determined by characteristics of the patients treated. A randomized, double-blind study used 24-hour ambulatory blood pressure (BP) monitoring to compare the effects of 2 beta blockers, bisoprolol (10 to 20 mg; n = 107) and atenolol (50 to 100 mg; n = 96), administered once daily in 4 population groups. After a 4-week placebo period, patients with an office diastolic BP between 95 and 114 mm Hg were stratified according to race and age, and were randomly assigned to treatment with bisoprolol or atenolol for 8 weeks. BP averages measured by automated monitoring for the 24-hour periods were compared between groups. In elderly patients, the reductions in both average 24-hour systolic and diastolic BP were greater with bisoprolol than with atenolol (13 +/- 3/13 +/- 1 mm Hg [n = 23] vs 4 +/- 2/6 +/- 1 mm Hg [n = 30]; p < 0.01). Similarly, bisoprolol produced greater reductions in average 24-hour diastolic BP than did atenolol in nonblack patients (16 +/- 2/12 +/- 1 mm Hg [n = 85] vs 12 +/- 2/9 +/- 1 mm Hg [n = 83]; p = 0.02). Bisoprolol and atenolol were similar in the black (10 +/- 5/9 +/- 3 mm Hg [n = 22] and 10 +/- 6/6 +/- 3 mm Hg [n = 13], respectively) and young (15 +/- 1/11 +/- 1 mm Hg [n = 84] and 16 +/- 2/10 +/- 1 mm Hg [n = 66], respectively) groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8517426     DOI: 10.1016/0002-9149(93)90216-y

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Clinical pharmacology-physiology conference. A chrono-therapeutic approach to the treatment of hypertension.

Authors:  D T Lowenthal; J Estrada; R Cott
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  The Impact of Beta Blockers on Survival in Heart Transplant Recipients: Insights from the Zabrze HTx Registry.

Authors:  Grzegorz M Kubiak; Radosław Kwieciński; Agnieszka Ciarka; Andrzej Tukiendorf; Piotr Przybyłowski; Tomasz Hrapkowicz; Michał O Zembala
Journal:  Cardiol Res Pract       Date:  2020-07-23       Impact factor: 1.866

3.  A new antihypertensive strategy for black patients: low-dose multimechanism therapy.

Authors:  E Saunders; J Neutel
Journal:  J Natl Med Assoc       Date:  1996-03       Impact factor: 1.798

Review 4.  Improving patient compliance: a major goal in the management of hypertension.

Authors:  Joel M Neutel; David H G Smith
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Mar-Apr       Impact factor: 3.738

5.  In Silico comparison between metoprolol succinate and bisoprolol on 24-hour systolic blood pressures.

Authors:  Sven-Olof Jansson; Anders E Malm; Torbjörn Lundström
Journal:  Drugs R D       Date:  2014-12

6.  Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials.

Authors:  Joyce P Samuel; Joshua A Samuels; Lauren E Brooks; Cynthia S Bell; Claudia Pedroza; Donald A Molony; Jon E Tyson
Journal:  Trials       Date:  2016-01-08       Impact factor: 2.279

Review 7.  Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.

Authors:  Waleed AlHabeeb; Sanaa Mrabeti; Ahmed Adel Ibrahim Abdelsalam
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-09       Impact factor: 3.947

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.